|
|
Volumn 31, Issue 5, 2013, Pages 379-382
|
|
Antimicrobial peptides stage a comeback
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ARENICIN;
AVIDOCIN;
BACTERIOCIN;
IMX 924;
LYTIXAR;
MAGAININ DERIVATIVE;
MU 1140;
NOVEXATIN;
NVB 302;
OMIGANAN;
OP 145;
PEPTOID;
PEXIGANAN;
POLYPEPTIDE ANTIBIOTIC AGENT;
PUROCIN;
UNCLASSIFIED DRUG;
VANCOMYCIN;
ANTIBIOTIC RESISTANCE;
ARTICLE;
CLINICAL TRIAL (TOPIC);
CLOSTRIDIUM DIFFICILE INFECTION;
DRUG HYDROLYSIS;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG MECHANISM;
DRUG SCREENING;
DRUG SYNTHESIS;
FOOD AND DRUG ADMINISTRATION;
INNATE IMMUNITY;
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;
MYCOBACTERIUM TUBERCULOSIS;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
ANTI-INFECTIVE AGENTS;
ANTIMICROBIAL CATIONIC PEPTIDES;
BACTERIAL INFECTIONS;
DRUG APPROVAL;
HUMANS;
UNITED STATES;
|
|
EID: 84877318780
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt.2572 Document Type: Article |
|
Times cited : (450)
|
|
References (0)
|
